報價延遲最少15分鐘:2025/08/25 13:59 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
37.86 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
11.29/-7.60
|
|
企業價值
2.29B
|
| 資產負債 |
|
每股賬面淨值
23.57
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
36.50M
|
|
每股收益
0.41
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/08/25 13:59 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others. |
